Booz Allen Hamilton enters its fiscal second-quarter report with an unusual mix of improving signals and shrinking numbers. Last quarter, funding, bookings and funded backlog all turned sharply higher after a punishing fiscal 2026, and margins hit their best level in more than a year. Revenue, however, kept falling, and management warned that civil sales would drop by double digits sequentially this quarter. The question for the October 23 report is whether the order book recovery is real enough to outweigh a quarter that management has already told the Street will look worse.
Consensus calls for earnings of $1.44 per share on revenue of $2.80 billion, down 3.4% and 3.1% from a year ago. That is a clear step down from last quarter's $1.81, which beat expectations on the strength of an 11.9% adjusted EBITDA margin. The Earnings Whisper sits at $1.54, a meaningful 10 cents above consensus, suggesting that some investors believe the margin gains from last year's $150 million cost takeout and the early shift toward fixed-price work are stickier than the published numbers assume. The full-year picture adds tension. Management reaffirmed fiscal 2027 guidance of $6.00 to $6.35 per share on revenue of $11.2 billion to $11.7 billion, and consensus sits at $6.31, near the top of the earnings range, while the $11.41 billion revenue estimate lands comfortably mid-range. Adding the first-quarter result to this quarter's estimate leaves roughly $3.06 to reach the Street's annual number, even though management has said margins will ease in the back half. Analysts are effectively betting on execution near the ceiling of a guide the company declined to raise.
The most important evidence will be whether last quarter's demand inflection carries forward. Funded backlog swung to a 15% year-over-year gain, national security funded backlog rose 23%, and book-to-bill jumped to 1.5 times from 0.3 times just two quarters earlier. Another quarter of book-to-bill near or above 1.0 and continued funded backlog growth would validate the idea that fiscal 2026 marked the trough. A relapse would suggest the first quarter was boosted by lumpy awards such as the record $2.7 billion EMAPS 3 renewal. National security revenue also needs to start moving. It grew only 1% last quarter against a mid-single-digit full-year target that management described as back-half weighted, so flat revenue this quarter despite a sharp civil decline would imply defense and intelligence are finally picking up the slack.
The pending Ultra Mission Solutions acquisition, expected to close this quarter, is a potential upside lever because its double-digit growth and margins above 20% are not in guidance. Any commentary on how it shifts the outlook could matter as much as the quarterly numbers. On the risk side, headcount was down about 7% and cleared hiring was lagging, which could cap how quickly backlog converts to revenue. Elevated days sales outstanding, the fixed-price transition potentially delaying awards, and a midterm-year budget process with several unresolved Congressional items all leave room for a cautious second-half tone.
The market has not given management much credit. Shares are up 2.7% since the last report, trailing the S&P 500 by 1.5 points, and at $71.87 the stock sits below its 200-day moving average of $77.26 and in the lower half of its post-earnings range of $65.88 to $81.19. Sentiment is roughly 31% bearish, essentially unchanged from a quarter ago, so skepticism has neither faded nor deepened.
Ultimately, this report hinges on conversion. If funding and bookings stay strong while margins hold close enough to keep the high end of guidance credible, the early improvement story graduates toward a genuine recovery. If backlog momentum stalls just as civil revenue falls, the first quarter will look more like a pause in the decline than a turn.